Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomised, Assessor-Blind, Comparative Efficacy Clinical Trial of 3 Pediculicides.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00381082
Recruitment Status : Completed
First Posted : September 27, 2006
Last Update Posted : December 12, 2006
Sponsor:
Collaborator:
Ego Pharmaceuticals
Information provided by:
Uniquest Pty Ltd

Brief Summary:

Objective

To compare the cure rates (defined as the complete absence of live lice, adults or nymphs, as diagnosed by wet-combing of three Australian approved head lice products for the treatment of primary school children with head lice infestation. The study design will be randomised and assessor-blind using three comparative parallel treatment groups.

The study population will consist of Queensland state primary school children (up to Year 7) with live head lice (adults or nymphs) on the hair or scalp who have not used any head lice product in the four weeks prior to the study.


Condition or disease Intervention/treatment Phase
Pediculosis Drug: 1) MOOV Head Lice Treatment (Ego Pharmaceutical). Drug: Banlice Mousse Aerosol (Pfizer, Australia) Drug: 3) KP24 Medicated Foam (Nelson Laboratories) Phase 2 Phase 3

Detailed Description:
All products were used according to the manufacturer's instructions. KP24 and Banlice were applied twice separated by a one week interval. MOOV Head Lice Treatment was applied on Day 0, Day 7 and Day 14. The cure rate (absence of live lice) one day after the first administration for all products was a secondary outcome measure. The cure rate at 7 days after the final administration (Day 14 for Banlice or KP24 and at Day 21 for MOOV Head Lice Treatment) was the primary outcome measure. Siblings were treated if these were found to be infected as an enrolment criteria.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Randomised, Controlled and Blinded Assessment Study of the Efficacy of MOOV Head Lice Treatment (Ego Pharmaceutical Pty. Ltd.) in the Treatment of Head Lice in Primary School Children.
Study Start Date : September 2004
Study Completion Date : November 2004



Primary Outcome Measures :
  1. Absence of live head lice one week after the last treatment for each product (ie at Day 14 for KP24 and Banlice and at Day 21 for MOOV Head Lice Treatment)

Secondary Outcome Measures :
  1. Absence of live head lice one day after the first treatment of each product


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female primary school children.
  • Presence of live head lice (adults or nymphs) on the hair or scalp. The presence of live lice will be determined from a visual inspection of the hair and scalp and Dry-combing of the hair. Combing will stop immediately once live lice are observed. The presence of lice eggs alone is not a sufficient condition for inclusion in the trial.
  • Be available for the duration of the trial.
  • Parent / Guardian is willing not to use other head lice products or methods (e.g. combs) to treat their child’s head lice for 21 days after the first treatment.
  • Parent / Guardian has given written informed consent to their child’s participation in the trial.

Exclusion Criteria:

  • History of allergies or adverse reactions to head lice products or the components of the specific products being tested.
  • Treatment with any head lice product in the month prior to Day 0.
  • Presence of scalp disease(s).
  • If a subject has a sibling in Grade 1-7 this sibling must also be enrolled in the study and treated on Day 0 otherwise the subject must be considered ineligible for enrolment.
  • Subjects must have one fixed place of residence

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00381082


Locations
Layout table for location information
Australia, Queensland
University of Queensland
Brisbane, Queensland, Australia, 4072
Sponsors and Collaborators
Uniquest Pty Ltd
Ego Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Stephen Barker, PhD The University of Queensland

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00381082     History of Changes
Other Study ID Numbers: MOOV-1 Version 1 22 Sep 2004
First Posted: September 27, 2006    Key Record Dates
Last Update Posted: December 12, 2006
Last Verified: December 2006

Keywords provided by Uniquest Pty Ltd:
Pediculus
capitis
lice

Additional relevant MeSH terms:
Layout table for MeSH terms
Lice Infestations
Ectoparasitic Infestations
Skin Diseases, Parasitic
Parasitic Diseases
Skin Diseases, Infectious
Skin Diseases